WO2006084757A3 - Combination of ca/mg salt of valsartan with an antidiabetic agent - Google Patents

Combination of ca/mg salt of valsartan with an antidiabetic agent Download PDF

Info

Publication number
WO2006084757A3
WO2006084757A3 PCT/EP2006/001285 EP2006001285W WO2006084757A3 WO 2006084757 A3 WO2006084757 A3 WO 2006084757A3 EP 2006001285 W EP2006001285 W EP 2006001285W WO 2006084757 A3 WO2006084757 A3 WO 2006084757A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
insulin
fructose
valsartan
combination
Prior art date
Application number
PCT/EP2006/001285
Other languages
French (fr)
Other versions
WO2006084757A2 (en
Inventor
John Glasspool
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
John Glasspool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006084757(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Novartis Pharma Gmbh, John Glasspool filed Critical Novartis Ag
Publication of WO2006084757A2 publication Critical patent/WO2006084757A2/en
Publication of WO2006084757A3 publication Critical patent/WO2006084757A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises (i) the calcium or magnesium salt of the AT1 receptor antagonist (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[21-(1 H-tetrazol-5-yl)-biphenyl-4-yl-rnethyl]-amine (valsartan) and (ii) at least one antidiabetic compound, preferably selected from the group consisting of a dipeptidyl peptidase IV (DPP IV) inhibitor, insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists.
PCT/EP2006/001285 2005-02-14 2006-02-13 Combination of ca/mg salt of valsartan with an antidiabetic agent WO2006084757A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0503062.2 2005-02-14
GBGB0503062.2A GB0503062D0 (en) 2005-02-14 2005-02-14 Combination of organic compounds

Publications (2)

Publication Number Publication Date
WO2006084757A2 WO2006084757A2 (en) 2006-08-17
WO2006084757A3 true WO2006084757A3 (en) 2006-11-23

Family

ID=34385460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001285 WO2006084757A2 (en) 2005-02-14 2006-02-13 Combination of ca/mg salt of valsartan with an antidiabetic agent

Country Status (6)

Country Link
AR (1) AR053128A1 (en)
GB (1) GB0503062D0 (en)
GT (1) GT200600049A (en)
PE (1) PE20061008A1 (en)
TW (1) TW200638928A (en)
WO (1) WO2006084757A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006253A1 (en) * 2000-07-19 2002-01-24 Novartis Ag Valsartan salts
WO2003099279A1 (en) * 2002-05-29 2003-12-04 Novartis Ag Combination of a dpp iv inhibitor and a cardiovascular compound
WO2005025673A1 (en) * 2003-09-08 2005-03-24 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
WO2005084666A1 (en) * 2004-03-02 2005-09-15 Abeille Pharmaceuticals, Inc. Co-formulations of kits of bioactive agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006253A1 (en) * 2000-07-19 2002-01-24 Novartis Ag Valsartan salts
WO2003099279A1 (en) * 2002-05-29 2003-12-04 Novartis Ag Combination of a dpp iv inhibitor and a cardiovascular compound
WO2005025673A1 (en) * 2003-09-08 2005-03-24 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
WO2005084666A1 (en) * 2004-03-02 2005-09-15 Abeille Pharmaceuticals, Inc. Co-formulations of kits of bioactive agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.", JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 21, 2003, pages 761 - 769, XP008067334, ISSN: 0263-6352 *
"HIGHLIGHTS OF THE 37TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)", PRACTICAL DIABETES INTERNATIONAL, PROFESSIONAL, MANAGERIAL AND HEALTHCARE PUBLICATIONS,, GB, vol. 18, no. 9, November 2001 (2001-11-01), pages 332 - 337, XP008011490, ISSN: 1357-8170 *
LEDINGHAM JM AND LAVERTY R: "Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, XX, XX, vol. 32, no. 11, 2005, pages 919 - 925, XP008067346 *

Also Published As

Publication number Publication date
TW200638928A (en) 2006-11-16
WO2006084757A2 (en) 2006-08-17
PE20061008A1 (en) 2006-11-29
GB0503062D0 (en) 2005-03-23
GT200600049A (en) 2006-09-07
AR053128A1 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
WO2001052825A3 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
HU0400405D0 (en) Novel compounds
WO2006070195A8 (en) Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
MX2009005358A (en) 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
MX2009005174A (en) 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
WO2009034029A3 (en) 1-substituted 4-heterocyclylpiperidines for use as cgrp antagonists
WO2008088727A3 (en) Endothelin receptor antagonists
WO2006084757A3 (en) Combination of ca/mg salt of valsartan with an antidiabetic agent
WO2009009122A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2005118558A3 (en) Pyrimidine compounds and use thereof
WO2006100026A8 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
WO2007102446A3 (en) Method and composition for treating chronic obstructive pulmonary disease
WO2006067215A3 (en) Intermediate compounds for the preparation of angiotensin ii receptor antagonists
WO2005114206A3 (en) Diagnostics and therapeutics for diseases associated with serotonin 5-ht5a receptor (5ht5a)
TH107927B (en) New pyrazolo pyrimidine is a cyclin-dependent kinase inhibitor.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06706897

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6706897

Country of ref document: EP